News & Updates

Show Multimedia Only

Social media posts show difficulties faced by sarcoma patients

An analysis of social media posts reveals the interconnected challenges that patients with sarcoma have to go through, including treatment decisions, financial concerns, and work impact.

Social media posts show difficulties faced by sarcoma patients

19 hours ago

Subcutaneous on par with IV pembrolizumab for NSCLC

20 hours ago by

Pembrolizumab administered subcutaneously (SC) is noninferior to the intravenous (IV) strategy in terms of overall exposure and trough concentrations, with similar efficacy and consistent safety profiles in patients with treatment-naive metastatic nonsmall cell lung cancer (NSCLC), reports a study.

Subcutaneous on par with IV pembrolizumab for NSCLC

20 hours ago

Bevacizumab plus erlotinib shows promise in hereditary, sporadic papillary kidney cancer

a day ago

Combination treatment with bevacizumab plus erlotinib appears to work against hereditary leiomyomatosis and renal-cell cancer (HLRCC)-associated or sporadic papillary renal-cell carcinoma, according to an open-label phase II study.

Bevacizumab plus erlotinib shows promise in hereditary, sporadic papillary kidney cancer

a day ago

RA onset delayed through 4 years with 1-year abatacept treatment in at-risk individuals

16 Jul 2025 by

A 12-month therapeutic intervention with self-administered abatacept can delay the onset of rheumatoid arthritis (RA) in at-risk individuals for up to 4 years, according to results from the ALTO follow-up study presented at EULAR 2025.

RA onset delayed through 4 years with 1-year abatacept treatment in at-risk individuals

16 Jul 2025

Nurulimab-prolgolimab superior to prolgolimab alone in metastatic melanoma

11 Jul 2025 by

First-line nurulimab and prolgolimab combination therapy demonstrated superior efficacy compared with prolgolimab monotherapy in patients with unresectable or metastatic melanoma, according to the OCTAVA trial presented at AACR 2025.

Nurulimab-prolgolimab superior to prolgolimab alone in metastatic melanoma

11 Jul 2025

Pembrolizumab + CCRT ups survival in high-risk LACC

10 Jul 2025 by

Treatment with the combination of pembrolizumab and concurrent chemoradiotherapy (CCRT), followed by pembrolizumab maintenance, led to a sustained, long-term survival benefit in patients with high-risk, locally advanced cervical cancer (LACC) compared with CCRT alone, according to the final analysis of the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial presented at ASCO 2025.

Pembrolizumab + CCRT ups survival in high-risk LACC

10 Jul 2025

Does testosterone level predict metastasis-free survival in nmCRPC?

09 Jul 2025

Maintenance serum testosterone levels ≥20 ng/dL do not appear predictive of worse metastasis-free survival (MFS) among men with testosterone <50 ng/dL on first-line therapy of nonmetastatic castration-resistant prostate cancer (nmCRPC) using novel hormonal agents, according to a study.

Does testosterone level predict metastasis-free survival in nmCRPC?

09 Jul 2025

Structured exercise after adjuvant chemotherapy for colon cancer extend overall survival

09 Jul 2025 by

A structured exercise programme offered alongside health education materials may prolong overall survival (OS) in patients with resected colon cancer who have completed adjuvant chemotherapy, according to the final results of the phase III CHALLENGE trial presented at ASCO 2025.

Structured exercise after adjuvant chemotherapy for colon cancer extend overall survival

09 Jul 2025

Linperlisib plus chidamide shows therapeutic potential in cutaneous T-cell lymphoma

08 Jul 2025

Combination treatment with the PI3Kδ inhibitor linperlisib plus the histone deacetylase inhibitor chidamide has demonstrated promising clinical activity in relapsed or refractory cutaneous T-cell lymphoma (CTCL) in a phase I study.

Linperlisib plus chidamide shows therapeutic potential in cutaneous T-cell lymphoma

08 Jul 2025

Aspirin use may prevent CRC metastasis

07 Jul 2025

The use of aspirin appears to provide protective benefits against metastasis in patients with colorectal cancer (CRC), reports a study.

Aspirin use may prevent CRC metastasis

07 Jul 2025

News & Updates

Filter by Specialty:

Specialty:

Social media posts show difficulties faced by sarcoma patients

Social media posts show difficulties faced by sarcoma patients

Subcutaneous on par with IV pembrolizumab for NSCLC

Subcutaneous on par with IV pembrolizumab for NSCLC

Bevacizumab plus erlotinib shows promise in hereditary, sporadic papillary kidney cancer

Bevacizumab plus erlotinib shows promise in hereditary, sporadic papillary kidney cancer

RA onset delayed through 4 years with 1-year abatacept treatment in at-risk individuals

RA onset delayed through 4 years with 1-year abatacept treatment in at-risk individuals

Nurulimab-prolgolimab superior to prolgolimab alone in metastatic melanoma

Nurulimab-prolgolimab superior to prolgolimab alone in metastatic melanoma

Pembrolizumab + CCRT ups survival in high-risk LACC

Pembrolizumab + CCRT ups survival in high-risk LACC

Does testosterone level predict metastasis-free survival in nmCRPC?

Does testosterone level predict metastasis-free survival in nmCRPC?

Structured exercise after adjuvant chemotherapy for colon cancer extend overall survival

Structured exercise after adjuvant chemotherapy for colon cancer extend overall survival

Linperlisib plus chidamide shows therapeutic potential in cutaneous T-cell lymphoma

Linperlisib plus chidamide shows therapeutic potential in cutaneous T-cell lymphoma

Aspirin use may prevent CRC metastasis

Aspirin use may prevent CRC metastasis